A Non-interventional Study to Further Characterize the Safety and Effectiveness of Sildenafil in the Treatment of Pulmonary Arterial Hypertension (PAH) in Adults From China in a Real World Setting
Latest Information Update: 21 Apr 2023
At a glance
- Drugs Sildenafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Pfizer Pharma
- 17 Apr 2023 Status changed from active, no longer recruiting to completed.
- 22 Sep 2022 New trial record